Introduction: A New Era in Oral GLP-1 Therapy
On 10 August 2026, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorisation to orforglipron (brand name Foundayo®), making the United Kingdom the first country in Europe to approve this novel oral weight-loss and diabetes treatment. Developed by Eli Lilly, orforglipron is a non-peptide, small-molecule GLP-1 receptor agonist taken as a once-daily oral capsule.
This approval marks a significant milestone in the GLP-1 landscape, following the MHRA’s authorisation of Novo Nordisk’s oral semaglutide (Wegovy® pill) in June 2026. Unlike its injectable and peptide-based oral predecessors, orforglipron offers the convenience of oral administration without food or water restrictions, potentially expanding access to patients who have previously avoided injectable therapies. The drug is indicated for adults with a BMI of 30 or above, or a BMI of 27–30 with at least one weight-related comorbidity, and for improving glycaemic control in patients with insufficiently controlled type 2 diabetes.
Mechanism of Action: A Distinct Pharmacological Profile
Orforglipron represents a departure from traditional peptide-based GLP-1 receptor agonists (RAs) like semaglutide and liraglutide.
Non-Peptide Small-Molecule Structure
Unlike peptide GLP-1 RAs, which are large molecules that require injection or special absorption enhancers (like SNAC for oral semaglutide), orforglipron is a small-molecule non-peptide agonist. This structural difference allows for reliable oral absorption independent of food intake.
Biased G-Protein Signalling
Orforglipron binds to a distinct site on the GLP-1 receptor—the upper helical bundle—rather than the orthosteric peptide binding site used by endogenous GLP-1. It acts as a G-protein-biased partial agonist that:
- Stimulates cyclic AMP (cAMP) production via Gs protein signalling, which is the primary pathway for GLP-1’s metabolic effects
- Exhibits minimal β-arrestin recruitment, which reduces receptor internalisation and desensitisation
- Has low intrinsic efficacy for effector activation, meaning it requires lower receptor occupancy to achieve a full biological response
This biased signalling profile may contribute to a favourable efficacy-tolerability balance.
Pharmacokinetic Properties
Clinical Efficacy: Evidence from Phase 3 Trials
Glycaemic Control in Type 2 Diabetes
The landmark ACHIEVE-3 trial, published in The Lancet (March 2026), directly compared orforglipron with oral semaglutide in 1,698 patients with type 2 diabetes inadequately controlled on metformin.
| Parameter | Orforglipron 12 mg | Orforglipron 36 mg | Semaglutide 7 mg | Semaglutide 14 mg |
|---|---|---|---|---|
| Baseline HbA1c | 8.3% | 8.3% | 8.3% | 8.3% |
| HbA1c reduction at 52 weeks | –1.71% | –1.91% | –1.23% | –1.40% |
| Achieved HbA1c <5.7% | — | ~37.5%* | — | 12.5% |
*Approximate based on reported three-fold higher achievement
Key findings:
- Orforglipron was non-inferior and superior to oral semaglutide for HbA1c reduction
- Orforglipron 36 mg lowered HbA1c by 0.33% more than semaglutide 14 mg
- Orforglipron 12 mg lowered HbA1c by 0.48% more than semaglutide 7 mg
A meta-analysis of three RCTs (2,505 participants) confirmed a dose-dependent HbA1c reduction ranging from –0.80% at 3 mg to –1.67% at 45 mg.
Weight Loss
| Parameter | Orforglipron (24 mg) | Placebo |
|---|---|---|
| Body weight reduction | –7.80% | Reference |
| BMI reduction | –2.70 kg/m² (45 mg) | Reference |
| Waist circumference reduction | –5.90 cm (24 mg) | Reference |
A systematic review reported a mean body weight reduction of –9.34% with higher orforglipron doses.
Cardiometabolic Benefits
A meta-analysis of four large trials demonstrated consistent, dose-dependent improvements across multiple cardiovascular risk factors:
| Parameter | Mean Reduction/Change |
|---|---|
| Body weight | –6.08% (up to –9.31% at higher doses) |
| Systolic blood pressure | –4.32 mmHg (up to –5.78 mmHg at 45 mg) |
| LDL-cholesterol | –4.14% |
| Triglycerides | –10.90% |
| VLDL-cholesterol | –10.81% |
| HDL-cholesterol | +3.31% (increase) |
Notably, heterogeneity was very low to absent (I² = 0%) for blood pressure and lipid outcomes, indicating highly consistent effects.
Safety Profile and Adverse Effects
Common Side Effects
As with other GLP-1 RAs, gastrointestinal side effects are the most frequently reported:
In the ATTAIN-1 trial, gastrointestinal adverse events occurred in 64.7% of orforglipron-treated patients vs 37.5% with placebo, and were mostly mild to moderate in severity. Adverse events leading to discontinuation occurred in 5–10% of orforglipron-treated participants vs 3% with placebo.
Serious Warnings and Precautions
The prescribing information includes warnings for:
| Warning | Clinical Significance |
|---|---|
| Pancreatitis | Acute pancreatitis has been reported; discontinue if suspected |
| Gallbladder disease | Including cholelithiasis and cholecystitis |
| Acute kidney injury | Often secondary to dehydration from GI side effects |
| Hypersensitivity reactions | Including anaphylaxis and angioedema |
| Thyroid C‑cell tumours | Boxed warning for risk of thyroid cancer (observed in animal studies) |
| Diabetic retinopathy complications | Particularly relevant in patients with rapid glycaemic improvement |
Hepatic Safety
A pooled analysis of 11,220 participants across seven Phase 3 trials (up to 104 weeks) found that orforglipron treatment was not associated with drug-induced liver injury. Orforglipron treatment was actually associated with mean reductions in ALT/AST levels, and the incidence of hepatic adverse events was balanced between orforglipron and comparators.
Adverse Events in Older Adults
A post-hoc analysis of adults over 65 years with obesity (with or without diabetes) found that adverse events were higher with orforglipron (12.3%) vs placebo (5.5%), with gastrointestinal events being the most common (64.7% vs 37.5%).
Drug Interactions
Orforglipron can interact with other medications through two primary mechanisms:
Interactions Affecting Orforglipron Levels (CYP3A4 Metabolism)
Interactions Where Orforglipron Affects Other Drugs (Gastric Emptying)
Dosing and Administration
UK Access and Availability
Comparison: Orforglipron vs Oral Semaglutide (Wegovy® Pill)
Conclusion: A Transformative Addition to GLP-1 Therapy
Orforglipron represents a significant advancement in the GLP-1 RA landscape. Its non-peptide, small-molecule structure enables:
- Reliable once-daily oral administration without food or water restrictions, improving convenience and potentially adherence
- Superior glycaemic control compared to oral semaglutide in head-to-head trials
- Consistent cardiometabolic benefits, including weight loss, blood pressure reduction, and lipid improvements
- A favourable hepatic safety profile, with no evidence of drug-induced liver injury
However, clinicians should remain vigilant for the typical GLP-1 class gastrointestinal side effects, rare but serious risks including pancreatitis and gallbladder disease, and significant drug interactions, particularly with CYP3A4 modulators and oral contraceptives.
For patients, orforglipron offers a convenient, effective oral alternative to injectable GLP-1 RAs. For the healthcare system, it represents another tool in the expanding arsenal against obesity and type 2 diabetes—two of the most pressing public health challenges of our time.
As orforglipron becomes available through private prescription in the UK, and potentially through the NHS following NICE assessment, its real-world impact will become clearer. What is already evident is that the oral GLP-1 era is here, and orforglipron is a compelling new option in this rapidly evolving therapeutic landscape.
References
- Citeline. Lilly’s GLP-1 Pill Foundayo Approved In UK, Prioritized For Obesity HTA. 2026.
- Pharmaceutical Technology. UK regulators greenlight Lilly’s Foundayo, intensifying Novo competition. 2026.
- ADVFN. MedPal AI eyes private GLP-1 market after UK authorises Eli Lilly weight-loss pill. 2026.
- Ramadurgum P, et al. Potential nephroprotective mechanisms of orforglipron, an oral non-peptide GLP-1 receptor agonist. Front Pharmacol. 2026;17:1917800.
- Sloop KW, et al. The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron. Sci Transl Med. 2024;16(778):eadp5765.
- Emara A, et al. Efficacy and safety of orforglipron in obesity with type 2 diabetes mellitus: a GRADE-assessed meta-analysis. Diabetol Metab Syndr. 2026.
- HCPLive. ACHIEVE-3: Orforglipron Superior to Semaglutide for Type 2 Diabetes in Phase 3 Trial. 2025.
- Nauck MA, et al. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3). Lancet. 2026;407(10534):1147-1160.
- Wharton S, et al. Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis. Diabetes Obes Metab. 2026.
- Alper A, et al. Efficacy and safety of orforglipron on cardiometabolic outcomes: a meta-analysis and systematic review. Cardiovasc Diabetol Endocrinol Rep. 2026.
- Lilly. Orforglipron Compared with Oral Semaglutide in Type 2 Diabetes: Results from ACHIEVE-3. 2026.
- GoodRx. 9 Foundayo (Orforglipron) Interactions You Should Know About. 2026.
- Medscape. Foundayo (orforglipron) dosing, indications, interactions. 2026.
- ScienceDirect. ATTAIN-2: Orforglipron for the treatment of obesity in people with type 2 diabetes. 2025.
